Guild speaks out on CAMS, Priceline criticised and more
This week Pharmacy Guild National President George Tambassis appeared alongside the AMA’s South Australian branch president on 891 ABC Adelaide’s morning program, defending pharmacy’s position on selling complementary medicines.
“[The Guild] always encourage pharmacy owners to keep complementary medicines evidence-based,” he said. “But ultimately, the pharmacy owner decides what complementary medicines they keep in their pharmacy. Yes, we do sell [complementary] medicines in our pharmacies and yes there are conflicts and we deal with that in a transparent way.”
AJP covered the results of a wages poll that asked our readers what you think the profession could do to help remunerate pharmacists more highly. There was a clear winner: Fair Work Australia needs to increase the award rate.
The PSA, NPSA and the Guild all publicly released their King Review submissions this week, covering each group’s position on a variety of topics including: discounting; remuneration for professional services; wholesale funding; location rules; CPA negotiations; and more.
API’s CEO and managing director Stephen Roche announced his resignation, to be replaced by Richard Vincent, who is currently API’s general manager of Business Development, Operations and Strategy.
Meanwhile a Melbourne woman wrote an open letter to Priceline on Facebook complaining of being racially profiled in one of its stores. “As our friend paid for her lashes we noticed the security guard let two white women and an Asian woman exit the store without searching their bags,” wrote Hiwot Birhane, who is of Ethiopian background.
“The next woman to exit the store was black and her bag was searched. We then exited the store and all five of us were searched by the security guard and Marie (the acting store manager at the time).” A Priceline spokesperson told Yahoo7 that Birhane’s experience was “highly regrettable”.
A study of almost 10 million NSAIDs users published in the BMJ revealed a link between NSAIDs and heart failure. Growing evidence of its risks is leading readers to question whether pharmacists should be selling OTC NSAIDs at all.
And a government review of Chinese trials for new pharmaceutical drugs revealed large-scale fraud in the industry. It found more than 80% of the clinical trial data were “fabricated”.